Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01497665 · ClinicalTrials.gov registry record · Phase 2
GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)
A Phase 2 study, sponsored by Angiochem.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01497665 is a Phase 2 study that was terminated before completion, run by Angiochem. The registered enrollment target is 16 participants.
The verdict
NCT01497665, a Phase 2 study, was terminated before completion, sponsored by Angiochem.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in patients with brain metastases from non-small cell lung cancer (NSCLC).
Interventions
- DRUG GRN1005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01497665
The ClinicalTrials.gov registry entry for NCT01497665 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Angiochem, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GRN1005 is the first listed.
NCT01497665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01497665 about?
NCT01497665 is a clinical study titled "GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)". The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in patients with brain metastases from non-small cell lung cancer (NSCLC).
What is the current status of trial NCT01497665?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2011-11. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01497665?
The interventions under investigation include: GRN1005 (DRUG).
Who is sponsoring clinical trial NCT01497665?
This trial is sponsored by Angiochem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.